Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman J. Lacayo, MD, Maureen O’Brien, MD, Shweta Jain, Soheil Meshinchi, MD, PhD, Ron Yu, PhD, Dejan Juric, MD, Myron N. Chang, PhD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 1915.

https://doi.org/10.1182/blood.V108.11.1915.1915

Published: 2006

Journal Articles

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Steven Buck, MS, Ron Yu, MA, Chitra Saraiya, MS, Lorrie Douglas, BS, Howard Weinstein, MD, Myron Chang, MD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Gary V. Dahl, MD, Branimir Sikic, MD, Yaddanapudi Ravindranath, MD

Blood (2004) 104 (11): 1130.

https://doi.org/10.1182/blood.V104.11.1130.1130

Published: 2004

Journal Articles

Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines.

Jorge F. DiMartino, M.D., Ph.D., Norman J. Lacayo, M.D., Marie Varadi, M.S., Yaddanapudi Ravindranath, M.D., Ron Yu, Branimir Sikic, M.D., Susana C. Raimondi, M.D., Gary V. Dahl, M.D.

Blood (2004) 104 (11): 1106.

https://doi.org/10.1182/blood.V104.11.1106.1106

Published: 2004

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

Journal Articles

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

Norman J. Lacayo, Soheil Meshinchi, Paivi Kinnunen, Ron Yu, Yan Wang, Christianna M. Stuber, Lorrie Douglas, Romina Wahab, David L. Becton, Howard Weinstein, Myron N. Chang, Cheryl L. Willman, Jerald P. Radich, Robert Tibshirani, Yaddanapudi Ravindranath, Branimir I. Sikic, Gary V. Dahl

Blood (2004) 104 (9): 2646–2654.

https://doi.org/10.1182/blood-2003-12-4449

Published: 2004

NARROW

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

Email alerts

ASH Publications

American Society of Hematology

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only